Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

scientific article

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1006397256
P356DOI10.1038/SJ.BJC.6604442
P932PMC publication ID2453025
P698PubMed publication ID18542071
P5875ResearchGate publication ID5315485

P50authorArmando SantoroQ56335956
Alessandra BearzQ57079928
Federico CappuzzoQ37392605
Adolfo FavarettoQ38641988
Francesco GrossiQ52665537
P2093author name stringA Santoro
V Torri
M Marangolo
A Ceribelli
B Castagneto
G L Ceresoli
M Mencoboni
D Cortinovis
P A Zucali
F De Vincenzo
G Del Conte
S Salamina
P2860cites workSurvival from rare cancer in adults: a population-based studyQ54006928
A Survey of Exact Inference for Contingency TablesQ56432188
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerQ60449339
Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaQ61628213
Underrepresentation of patients 65 years of age or older in cancer-treatment trialsQ73311140
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug AdministrationQ81002008
Phase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaQ82892136
Severe rhabdomyolysis associated with pemetrexed-based chemotherapyQ83017468
Nonparametric Estimation from Incomplete ObservationsQ25938997
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.Q33196736
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II studyQ33348171
Pemetrexed in malignant pleural mesothelioma.Q33364969
Aging and cancer in America. Demographic and epidemiologic perspectivesQ33841117
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaQ34214330
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest GroupQ34295028
Advances in malignant mesotheliomaQ34459139
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patientsQ34485292
Multidisciplinary treatment of malignant pleural mesotheliomaQ34659099
Pleural mesothelioma: little evidence, still time to do trialsQ35903121
Biology and management of malignant pleural mesothelioma.Q36600505
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050.Q36617025
Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groupsQ36777126
Comprehensive geriatric assessment for older patients with cancerQ36815525
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.Q36815528
Assessment of tumor response in malignant pleural mesotheliomaQ36926206
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer GroupQ39214897
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesotheliomaQ44102242
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.Q44267257
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural MesotheliomaQ44405249
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer InstQ46726893
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).Q46835349
Participation of patients 65 years of age or older in cancer clinical trialsQ48006693
Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models.Q50754874
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectcarboplatinQ415588
malignant pleural mesotheliomaQ18557602
phase II clinical trialQ42824440
P304page(s)51-56
P577publication date2008-06-10
P1433published inBritish Journal of CancerQ326309
P1476titlePemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
P478volume99

Reverse relations

cites work (P2860)
Q37090808Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future
Q52672893Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
Q41847770FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma
Q33914000Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
Q36821171Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma
Q37449036Future developments in the management of malignant pleural mesothelioma
Q55346721Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.
Q56976088Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Q34293068Investigational approaches for mesothelioma
Q34513958Malignant pleural mesothelioma: an update on diagnosis and treatment options
Q37529848Malignant pleural mesothelioma: current treatments and emerging drugs.
Q43916997Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.
Q37866663Medical treatment of mesothelioma: anything new?
Q58580151Multimodality treatment of malignant pleural mesothelioma
Q33890499Novel systemic therapy against malignant pleural mesothelioma
Q36322856Optimization of response classification criteria for patients with malignant pleural mesothelioma.
Q33918135Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
Q45020726Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Q92591513Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy
Q37290519Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
Q37992694Systemic treatment of malignant pleural mesothelioma
Q37260408Systemic treatments for mesothelioma: standard and novel
Q90808642Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
Q40466065miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
Q42412951microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.

Search more.